Table 1

Non-exhaustive list of diagnostic immunohistochemical markers217

Diagnosis*Antibody
Smooth muscle tumorsDesmin, h-caldesmon, smooth muscle actin
Fumarate hydratase deficiencyFH and 2SC
STUMPATRX, RB, PTEN, p53, DAXX, MTAP, MDM2
RhabdomyosarcomaDesmin, myogenin, MyoD1, myogenin
Inflammatory myofibroblastic tumorALK, ROS1
Endometrial stromal tumorsCD10, IFITM1, Cyclin D1, BCOR, ER, PR
SMARC-deficient tumorsBRG1 (SMARCA4), BRM (SMARCA2), INI/BAF47(SMARCB1), MMR (MLH1, PMS2, MSH6, MSH2)
PEComaHMB45, Melan A, Cathepsin K, TFE3
Fibrosarcomapan-TRK, CD34, S100
Solitary fibrous tumorSTAT6, CD34
Extraintestinal gastrointestinal stromal tumorc-KIT, DOG1
Complex genomic sarcomas (LMS, UUS)p53 (usually aberrant)
Simple genomic sarcomas (LG-ESS, HG-ESS, NTRK, etc)p53 (usually wild-type)
Uterine tumor resembling ovarian sex cord tumorCalretinin, inhibin
  • *The diagnosis can be established by a combination of these antibodies and integrated into the appropriate morphological context.

  • HG-ESS, high-grade endometrial stromal sarcoma; LG-ESS, low-grade endometrial stromal sarcoma; LMS, leiomyosarcoma; NTRK, neurotrophic tyrosine receptor kinase; PEComa, perivascular epithelial cell tumor; STUMP, smooth muscle tumor of uncertain malignant potential; UUS, undifferentiated uterine sarcoma.